Which has stronger earnings & valuation, TARA or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is TARA or JBIO more profitable?

Protara Therapeutics' return on equity of -38.70% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Jade Biosciences N/A -51.34% -47.32%

Which has preferable earnings and valuation, TARA or AKTS?

Aktis Oncology has higher revenue and earnings than Protara Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Aktis Oncology $6.50M 159.13 N/A N/A N/A

Is TARA or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Aktis Oncology N/A N/A N/A

Which has stronger earnings and valuation, EVO or TARA?

Protara Therapeutics has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 1.15 -$117.12M N/A N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Protara Therapeutics (TARA) Competitors

$4.22 -0.12 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 +0.08 (+1.90%)

As of 05:37 PM Eastern

Compare

TARA vs. COLL, JBIO, AKTS, EVO, and DBVT

Should you buy Protara Therapeutics stock or one of its competitors? MarketBeat compares Protara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protara Therapeutics include Collegium Pharmaceutical (COLL), Jade Biosciences (JBIO), Aktis Oncology (AKTS), Evotec (EVO), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Protara Therapeutics (NASDAQ:TARA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

38.1% of Protara Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Collegium Pharmaceutical has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Collegium Pharmaceutical	$780.57M	1.29	$62.87M	$2.04	15.23

In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 1 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.44 beat Collegium Pharmaceutical's score of 0.97 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Positive
Collegium Pharmaceutical	Positive

Protara Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Protara Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Protara Therapeutics currently has a consensus target price of $26.25, suggesting a potential upside of 522.04%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 85.13%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Collegium Pharmaceutical beats Protara Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Jade Biosciences?

Protara Therapeutics (NASDAQ:TARA) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Jade Biosciences is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Protara Therapeutics' return on equity of -38.70% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Jade Biosciences	N/A	-51.34%	-47.32%

Protara Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Protara Therapeutics currently has a consensus price target of $26.25, indicating a potential upside of 522.04%. Jade Biosciences has a consensus price target of $47.43, indicating a potential upside of 169.63%. Given Protara Therapeutics' higher probable upside, research analysts plainly believe Protara Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

38.1% of Protara Therapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Jade Biosciences had 21 more articles in the media than Protara Therapeutics. MarketBeat recorded 22 mentions for Jade Biosciences and 1 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.44 beat Jade Biosciences' score of 0.66 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Positive
Jade Biosciences	Positive

Summary

Protara Therapeutics beats Jade Biosciences on 10 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Aktis Oncology?

Protara Therapeutics (NASDAQ:TARA) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Aktis Oncology's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Aktis Oncology	N/A	N/A	N/A

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aktis Oncology had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Aktis Oncology and 1 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.44 beat Aktis Oncology's score of 0.68 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Positive
Aktis Oncology	Positive

Aktis Oncology has higher revenue and earnings than Protara Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Aktis Oncology	$6.50M	159.13	N/A	N/A	N/A

Protara Therapeutics presently has a consensus price target of $26.25, indicating a potential upside of 522.04%. Aktis Oncology has a consensus price target of $32.50, indicating a potential upside of 67.79%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Protara Therapeutics beats Aktis Oncology on 6 of the 10 factors compared between the two stocks.

How does Protara Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, Evotec and Evotec both had 1 articles in the media. Protara Therapeutics' average media sentiment score of 1.44 beat Evotec's score of 0.94 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evotec	Positive
Protara Therapeutics	Positive

Evotec has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Protara Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.15	-$117.12M	N/A	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

5.8% of Evotec shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Evotec presently has a consensus target price of $7.00, suggesting a potential upside of 142.21%. Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 522.04%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protara Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Protara Therapeutics	N/A	-38.70%	-36.02%

Summary

Protara Therapeutics beats Evotec on 8 of the 12 factors compared between the two stocks.

How does Protara Therapeutics compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Protara Therapeutics has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

DBV Technologies has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 173.04%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 522.04%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protara Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Protara Therapeutics' return on equity of -38.70% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Protara Therapeutics	N/A	-38.70%	-36.02%

In the previous week, DBV Technologies had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.44 beat DBV Technologies' score of 0.94 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
DBV Technologies	Positive
Protara Therapeutics	Positive

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats DBV Technologies on 11 of the 16 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$243.93M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-3.15	12.23	18.89	22.53
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	1.11	3.85	9.84	6.72
Net Income	-$57.44M	$75.85M	$3.57B	$337.19M
7 Day Performance	-11.34%	-1.67%	-1.16%	0.48%
1 Month Performance	-20.68%	22.18%	3.85%	5.07%
1 Year Performance	28.66%	21.83%	27.40%	34.25%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	3.4585 of 5 stars	$4.22 -2.8%	$26.25 +522.0%	+31.5%	$243.93M	N/A	N/A	30	Positive News Short Interest Decrease
COLL Collegium Pharmaceutical	2.5987 of 5 stars	$34.07 flat	$57.50 +68.8%	+4.0%	$1.11B	$780.57M	16.70	210
JBIO Jade Biosciences	2.5196 of 5 stars	$22.21 flat	$34.33 +54.6%	N/A	$1.10B	N/A	N/A	20	Trending News Analyst Forecast Analyst Revision Gap Up
AKTS Aktis Oncology	2.1439 of 5 stars	$20.34 flat	$32.00 +57.3%	N/A	$1.09B	$6.50M	N/A	76	Analyst Forecast Gap Down
EVO Evotec	3.0816 of 5 stars	$3.03 flat	$7.00 +131.0%	-25.9%	$1.08B	$891.97M	N/A	4,553

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. COLL, JBIO, AKTS, EVO, and DBVT

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Protara Therapeutics compare to Jade Biosciences?

Summary

How does Protara Therapeutics compare to Aktis Oncology?

Summary

How does Protara Therapeutics compare to Evotec?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. COLL, JBIO, AKTS, EVO, and DBVT

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Do institutionals & insiders have more ownership in TARA or COLL?

Which has better earnings & valuation, TARA or COLL?

Does the media refer more to TARA or COLL?

Which has more risk and volatility, TARA or COLL?

Is TARA or COLL more profitable?

Do analysts rate TARA or COLL?

Summary

How does Protara Therapeutics compare to Jade Biosciences?

Which has stronger earnings & valuation, TARA or JBIO?

Is TARA or JBIO more profitable?

Which has more risk & volatility, TARA or JBIO?

Do analysts recommend TARA or JBIO?

Do institutionals and insiders have more ownership in TARA or JBIO?

Does the media favor TARA or JBIO?

Summary

How does Protara Therapeutics compare to Aktis Oncology?

Is TARA or AKTS more profitable?

Do institutionals & insiders believe in TARA or AKTS?

Does the media refer more to TARA or AKTS?

Which has preferable earnings and valuation, TARA or AKTS?

Do analysts prefer TARA or AKTS?

Summary

How does Protara Therapeutics compare to Evotec?

Does the media refer more to EVO or TARA?

Which has more risk and volatility, EVO or TARA?

Which has stronger earnings and valuation, EVO or TARA?

Do institutionals and insiders have more ownership in EVO or TARA?

Do analysts prefer EVO or TARA?

Is EVO or TARA more profitable?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Which has stronger earnings and valuation, DBVT or TARA?

Which has more risk and volatility, DBVT or TARA?

Do analysts rate DBVT or TARA?

Is DBVT or TARA more profitable?

Does the media prefer DBVT or TARA?

Do insiders and institutionals have more ownership in DBVT or TARA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools